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A B S T R A C T
Autocrine vascular endothelial growth factor (VEGF) can regulate the survival and progression of cancers
through its various receptors. But the mechanisms and mediators for these functions are largely uncov-
ered, especially in breast cancer. We examined the potential roles and mechanisms of VEGF/neuropilin-1
(NRP-1) axis in regulating the tumorigenesis and metastasis of breast cancer and found the expression of
VEGF and NRP-1 correlated with aggressiveness of breast cancer. Knockdown of VEGF or NRP-1 inhibited
the proliferation, migration and invasion, but enhanced the apoptosis of MDA-MB-231 cells. In contrast,
induction of NRP-1 over-expression promoted the proliferation, migration and invasion of MCF-7 cells. VEGF
or NRP-1 silencing attenuated the epithelial-mesenchymal transition (EMT) process and the activation of NF-
κBp65, but enhanced GSK-3β expression in MDA-MB-231 cells while NRP-1 over-expression reversed the
effects in MCF-7 cells. Treatment with hVEGF165 did not change the inhibition in NRP-1 silencing MDA-
MB-231 cells, but enhanced the aggressiveness of NRP-1 over-expressing MCF-7 cells. In addition, VEGF-
silencing inhibited the growth and metastasis of implanted MDA-MB-231 tumors in vivo. Our novel data
suggest that the positive regulation of the VEGF/NRP-1 axis on the tumorigenesis and metastasis of breast
cancer may be associated with enhancing the EMT process and the NF-κB and β-catenin signaling. Hence,
the VEGF/NRP-1 axis may be a valuable target for design of therapies for intervention of breast cancer.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Vascular endothelial growth factor (VEGF or VEGF-A) can promote
vascular endothelial proliferation and angiogenesis [1]. VEGF-
mediated angiogenesis plays an essential role in the development,
progression andmetastasis of malignant tumors and VEGF is a ther-
apeutic target for treatment of many types of tumors, including
advanced colorectal cancer (CRC), non-small cell lung cancer (NSCLC)
and metastatic renal cell carcinoma (RCC) [2–5]. However, the ef-
ﬁcacy of VEGF targeting therapy is controversial in different types
of breast cancers. The variable effectiveness of VEGF-based
anti-angiogenesis therapy necessitates a better understanding of the
mechanisms by which VEGF regulates the growth and metastasis
of different types of cancers.
It is well known that VEGF can bind to its receptors, such as
VEGFR1 (FLT-1), VEGFR2 (FLK1/KDR) and VEGFR3 (FLT4). A previ-
ous study has shown that VEGF and VEGFR2 are co-expressed in
many types of tumors and associated with the development of re-
sistance to anti-angiogenesis therapy and radiotherapy [6]. Notably,
neuropilin-1 (NRP-1), a membrane protein, is a receptor for VEGF165
and VEGF189, and can stabilize the receptor complex. NRP-1 is ex-
pressed on several types of tumors and regulates the proliferation,
migration and invasion of tumor cells [7,8]. Furthermore, the tumor-
derived VEGF through VEGFR2 and NRP-1 creates a perivascular
niche to regulate the initiation and stemness of skin tumors [9]
and autocrine VEGF promotes the survival and invasion of pros-
tatic, pancreatic cancer and glioblastoma cells, particularly for cancer
stem-like cells in a NPR-1-dpendent manner [10–13]. One study
reveals that VEGF can support the survival of NRP-1 expressing breast
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cancer cells [14]. In addition, high levels of NRP-1 are expressed in
aggressively metastatic breast cancer MDA-MB-231 and MDA-MB-
435 cells [14–16]. However, the effect of VEGF/NRP-1 axis on the
tumorigenesis and metastasis of breast cancer and the molecular
mechanisms underlying the regulatory effect of this axis have not
been clariﬁed.
In the present study, we characterized the VEGF and NRP-1 ex-
pression in 48 freshly isolated breast cancer specimens and screened
their expression in several breast cancer cell lines. Subsequently,
we employed higher VEGF and NRP-1 expressing MDA-MB-231 and
higher VEGF and lower NRP-1 expressing MCF-7 cells to test the
impact of modulating VEGF or NRP-1 expression on the survival,
apoptosis, migration and invasion of breast cancer cells in vitro and
in vivo. Our data suggest that the regulation of VEGF/NRP-1 axis on
the tumorigenesis and invasion of breast cancer cells may be as-
sociated with enhancing the epithelial-mesenchymal transition (EMT)
process and the NF-κB and β-catenin signaling.
Materials and methods
A full description of materials andmethods, including immunohistochemical stain-
ing and evaluation, lentivirus infection, siRNA transfection, MTT assay, ﬂow cytometry
analysis, cell migration and invasion assays, ELISA andWestern blotting analysis, was
described in the Supplementary Data.
Patients and samples
The experimental protocol was approval by the Human Ethics Committee of the
First Aﬃliated Hospital of Xi’an Jiaotong University. Written informed consent was
obtained from individual patients. A total of 48 surgical primary tumor samples were
collected from patients with different stages of breast cancer at the inpatient service
of the Department of Oncology, the First Aﬃliated Hospital of Xi’an Jiaotong Uni-
versity from 2011 to 2013. Individual patients with breast cancer were diagnosed
by radiological images and biopsied tissue histology. The surgical tissue samples were
subjected to TNM stage, according to AJCC (the 6th version, 2002) and molecular
classiﬁcation analysis. Samples were excluded if the patients received any preop-
eratively adjuvant chemotherapy, radiotherapy or hormone therapy. Their clinical
pathological parameters are summarized in Table 1.
Breast cancer cell lines and culture
Human breast cancer T-47D, MDA-MB-231, MCF-7, SK-BR3 and MDA-MB-435S
cell lines at passages 3 to 15were obtained from Shanghai Cell Bank, Chinese Academy
of Sciences (Shanghai, China). All cells were cultured in RPMI1640 supplemented
with 10% fetal bovine serum (FBS), 100 Units/ml penicillin and 100 μg/ml strepto-
mycin (complete medium, Invitrogen, Shanghai, China) at 37 °C 5% CO2. The cells
at 70% of conﬂuency were harvested and the levels of VEGF, VEGFR and NRP-1 ex-
pression were determined by ELISA and Western blotting assays.
Orthotopic xenograft tumor model
The experimental protocols were approved by the Animal Care and Use Com-
mittee of Xi’an Jiaotong University. Female athymic nude mice at 4–6 weeks of age
were purchased from Silaike Laboratory Animal (Shanghai, China) and housed in a
speciﬁc pathogen free facility with free access to autoclaved water and food. Indi-
vidual mice were randomized and injected orthotopically with 2 × 106 MDA-MB-
231/shNC, or MDA-MB-231/shVEGF (0.2 ml in FBS-free medium) into their left fat
pad (n = 6 per group). The growth of implanted tumors wasmonitored using a vernier
caliper weekly up to 28 days post implantation. The volume of tumors was calcu-
lated using the formula: V = π[d2 × D]/6, where d is the minimal tumor diameter and
D is the maximum tumor diameter. At the end of this experiment, the mice were
subjected tomographic optical imaging using an IVIS imaging system (IVIS spec-
trum, Xenogen, USA) and sacriﬁced. Their tumor tissues and livers were dissected
out and imaged. The numbers of metastatic tumors in the livers were counted in a
blinded manner. The tumor tissue sections (4 μm) were analyzed by immunohis-
tochemistry using anti-PCNA and anti-Vimentin and the proliferation index (% of
cells with anti-PCNA positive nuclear staining) and the intensity of anti-Vimentin
staining were evaluated in a blinded manner.
Statistical analysis
Data are representative images or expressed as the mean ± SD/SEM. The differ-
ence among groups was determined by one-way ANOVA, two-tailed Student’s T test,
Mann–Whitney U or Fisher’s exact test when applicable. The difference in the growth
of implanted tumors between groups was determined by repeated ANOVA. All sta-
tistical analyses were performed using the SPSS 16.0 for Windows software (SPSS,
Chicago, USA). A p value of < 0.05 was considered statistically signiﬁcant.
Results
VEGF and NRP-1 expression vary in breast cancer tissues and cell
lines
To determine the potential role of VEGF/NRP-1 axis in the pro-
gression and metastasis of breast cancer, 48 human breast cancer
specimens were collected and the levels of VEGF and NRP-1 ex-
pression in the breast cancer tissues were characterized by
immunohistochemistry. High VEGF and NRP-1expression were de-
tected in the cytoplasm of cancer cells, whereas little staining was
observed in non-cancerous regions (Fig. 1A). Stratiﬁcation analy-
sis indicated that breast cancer tissues from patients with lymph
node metastasis had signiﬁcantly higher levels of VEGF and NRP-1
expression than those without lymph node metastasis (p = 0.008,
Table 1). However, there was no signiﬁcant association of VEGF/
NRP-1 expression with tumor stages, status (p = 0.440 and p = 0.925
respectively, Table 1) and ER, PR and Her2 status in this popula-
tion (p = 0.889, p = 0.425 and p = 0.589 respectively, Table 1).Hence,
VEGF and NRP-1 expression in breast cancer were associated pos-
itively with lymph node metastasis in this population.
Further ELISA analysis indicated that various levels of VEGF were
secreted by different breast cancer cell lines and increased with pro-
longed culture periods (Fig. 1B). As shown in Fig. 1C, higher levels
of NRP-1 expressionwere detected in highly aggressive breast cancer
MDA-MB-231 and MDA-MB-435S cells and lower levels of NRP-1
were observed in less aggressive MCF-7, SK-BR-3 and T-47D cells.
Western blot analysis revealed that variable levels of VEGFR1, but
not VEGFR3, were detected in different types of breast cancer cells
and high levels of VEGFR2 were detected only in MDA-MB-231 cells
(Fig. S1A). MDA-MB-231 and MCF-7 cells were chosen for further
study.
Table 1
The clinicopathologic characteristics of patients.
Characteristic Both lowa
(n = 24)
Intermediate
(n = 14)
Both high
(n = 10)
p value
Age 48 (29–77) 45 (36–65) 56 (42–72) 0.238b
Stagec
I–II 21 11 7 0.440
III 3 3 3
Tumor statusc
T1 10 5 3 0.925
T2–T4 14 9 7
Lymph nodal status
N0 16 3 2 0.008
N1–N3 8 11 8
ER
Negative 11 7 4 0.889
Positive 13 7 6
PR
Negative 11 9 4 0.425
Positive 13 5 6
HER-2
0 7 4 3 0.589
1+ 11 3 2
2+ 4 5 3
3+ 2 2 2
Data are real case numbers.
a Both low indicates that the levels of both NRP-1 and VEGF-A expression in tumor
cells are low; Intermediate indicates that the levels of either NRP-1 or VEGF-A ex-
pression in tumor cells is high, but not both; Both high indicates that the levels of
both NRP-1 and VEGF-A expression in tumor cells are high.
b Derived with a one-way ANOVA test and other p values were determined by Chi-
square test or Fisher’s exact test.
c The tumor stage, tumor status, and nodal status were classiﬁed according to the
international standards for staging breast cancer.
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The VEGF /NRP-1 axis is crucial for the proliferation and survival of
breast cancer cells
Previous studies have showed that VEGF/VEGFR2/NRP-1 axis can
regulate the proliferation of prostatic cancer and glioma cells [6,13].
To understand the importance of VEGF/NRP-1 axis in breast cancer,
stably VEGF-silencing MDA-MB-231/shVEGF cells and NRP-1 over-
expressing MCF-7/NRP-1 cells were generated. In addition, MDA-
MB-231 cells were transfected with NRP-1 speciﬁc siRNA to silence
NRP-1 expression. The knockdown eﬃciency of VEGF and NRP-1
mRNA transcripts was detected in breast cancer cells by real-time
PCR (Supplementary Fig. S1C and D). Interestingly, the relative levels
of NRP-1 expression in MDA-MB-231/shVEGF cells were obvi-
ously stronger than that in the controls, but there was no obvious
difference in the relative levels of VEGF expression between the
NRP-1 silencing MDA-MB-231 and control MDA-MB-231 cells
(Fig. 2A). Furthermore, induction of NRP-1 over-expression did not
affect the levels of VEGF expression in MCF-7 cells (Fig. 2A). Mor-
phologically, many MDA-MB-231/shVEGF and MDA-MB-231/
siNRP-1 cells became a rounded and triangle-like shape with a
smaller body size, as compared with their controls (Fig. 2B). In
contrast, many MCF-7/NRP-1 cells displayed a spindle-like shape
with increased body size (Fig. 2B).
Next, the impact of altered VEGF/NRP-1 expression on the pro-
liferation and apoptosis of breast cancer cells was determined. In
comparison with the control, knockdown of VEGF or NRP-1 sig-
niﬁcantly inhibited the proliferation of MDA-MB-231 cells (p < 0.01,
Fig. 3A) while NRP-1 over-expression signiﬁcantly enhanced the pro-
liferation of MCF-7 cells (p < 0.05, Fig. 3A). Intriguingly, treatment
with hVEGF165 slightly increased the proliferation of control MDA-
MB-231/siNC cells, while the same treatment did not change
signiﬁcantly the proliferation of MDA-MB-231/siNRP-1 cells. Treat-
ment with pan-caspase inhibitor Z-VAD-FMK signiﬁcantly increased
the proliferation of MDA-MB-231/siNRP-1 cells at the indicated time
points (p < 0.05, from 15.5% to 23.8%), but the same treatment just
moderately enhanced the proliferation of MDA-MB-231/shVEGF cells
(p > 0.05, from 5% to 14.4%). These data suggest that spontaneous
apoptosis of MDA-MB-231/siNRP-1 and MDA-MB-231/shVEGF cells
may contribute to their poor proliferation. Analysis of cell cycling
indicated that induction of NRP-1 over-expression in MCF-7 cells
increased the percentages of cells at S-phase regardless of the pres-
ence or absence of exogenous hVEGF165 (10 ng/ml) (p < 0.01, Fig. S2).
Fig. 1. VEGF and NRP-1 expression in breast cancer tissues and cell lines. The VEGF and NRP-1 expression in breast cancer and adjacent non-cancer tissue sections were
characterized by immunohistochemistry. The levels of VEGF in the supernatants of cultured breast cancer cells were determined by ELISA and the levels of NRP-1 expres-
sion in breast cancer cells were determined by Western blot assay. Data are representative images and expressed as the mean ± SD of each cell line from three separate
experiments. (A) Representative images of anti-VEGF and anti-NRP-1 staining in human breast cancer tissues and adjacent non-cancer tissues. (i) Invasive breast cancer,
Grade III; (ii) Invasive breast cancer, Grade III; (iii) Invasive breast cancer, Grade I; (iv) Invasive breast cancer, Grade II. (v–vi) adjacent non-cancer tissues; (vii-viii) Negative
IgG control. Bars: 50 μm. (B) ELISA analysis of the levels of VEGF secreted by breast cancer cells. (C) Western blot analysis of the relative levels of NRP-1 expression in breast
cancer cells.
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Moreover, ﬂow cytometry analysis revealed that VEGF or NRP-1
knockdown increased the percentages of early apoptotic MDA-MB-
231 cells (p < 0.05, Fig. 3B). Treatment with hVEGF165 did not change
the percentages of apoptotic MDA-MB-231/siNC andMDA-MB-231/
siNRP-1 cells (Fig. 3B). Hence, the VEGF/NRP-1 axis enhanced the
proliferation and survival of breast cancer cells in vitro.
The VEGF/NRP-1 axis promotes the invasion of breast cancer cells in
vitro
The impact of VEGF/NRP-1 axis on the invasion of breast cancer
cells was determined by transwell invasion assays. Because knock-
down of VEGF or NRP-1 in MDA-MB-231 cells increased the
frequency of apoptotic cells, MDA-MB-231/shVEGF, MDA-MB-231/
siNRP-1 and their controls were tested with or without hVEGF165
in the presence or absence of a pan-caspase inhibitor Z-VAD-FMK
and their invasionweremeasured at 36 h post treatment by transwell
invasion assays, respectively. Compared with MDA-MB-231/shNC
cells, the numbers of invaded MDA-MB-231/shVEGF cells were sig-
niﬁcantly reduced (p < 0.05, Fig. 4A). Similarly, the numbers of
invadedMDA-MB-231/siNRP-1 cells were signiﬁcantly less than that
of control MDA-MB-231/siNC cells (p < 0.05, Fig. 4B). While treat-
ment with hVEGF165 signiﬁcantly increased the numbers of invaded
MDA-MB-231/siNC cells (p < 0.05), the same treatment failed to
change the numbers of invaded MDA-MB-231/siNRP-1 cells. Sim-
ilarly, MCF-7/NC and MCF-7/NRP-1 cells in the presence or absence
of hVEGF165 were tested for their invasion at 36 h post culture by
transwell invasion assay. The numbers of invadedMCF-7/NRP-1 cells
were signiﬁcantly greater than that of MCF-7/NC cells (p < 0.001,
Fig. 4C). Treatmentwith hVEGF165 signiﬁcantly increased the numbers
of invadedMCF-7/NC andMCF-7/NRP-1 cells (p < 0.001). Similar pat-
terns of the migration of different groups of cells were observed
through transwell migration assay (Fig. S3). Thus, the VEGF/NRP-1
axis promoted the migration and invasion of breast cancer cells in
vitro.
The VEGF/NRP-1 axis promotes the EMT process of breast cancer cells
The migration and invasion of cancer cells are associated with
the EMT process. To understand the mechanisms underlying the
Fig. 2. Modulation of VEGF and NRP-1 expression changes morphologies of breast cancer cells. MDA-MB-231 cells were infected with lentivirus expressing VEGF-speciﬁc
shRNA or transfected with NRP-1-speciﬁc siRNA to silence VEGF or NRP-1 expression while MCF-7 cells were infected with lentivirus to induce NRP-1 over-expression. The
eﬃcacy of VEGF or NRP-1 silencing in MDA-MB-231 cells as well as NRP-1 over-expression in MCF-7 cells was determined byWestern blot assays. The morphological changes
in these cells were observed under a light microscope. Data are representative images of each group of cells from at least three separate experiments. (A) Western blot
analysis of the relative levels of VEGF and NRP-1 expression in MDA-MB-231 and MCF-7 cells after cell transfection. (B) The morphological changes in breast cancer
cells.
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Fig. 3. Modulation of VEGF or NRP-1 expression alters tumor cell proliferation and survival in vitro. The proliferation of different groups of cells in the presence or absence
of 10 ng/ml of hVEGF165 or pan-caspase inhibitor Z-VAD-FMK (50 μM) at the indicated time points was determined by MTT assay and their apoptosis at 24 h post culture
was characterized by ﬂow cytometry analysis. Data are representative ACS charts and expressed as the mean ± SEM of each group of cells at each time point from three
separate experiments. (A) Breast cancer cell proliferation. (B) Early apoptotic breast cancer cells (right lower quadrant). *p < 0.05, **p < 0.01 vs. the controls
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Fig. 4. Modulation of VEGF or NRP-1 expression alters the invasion of breast cancer cells. The different groups of MDA-MB-231 and MCF-7 breast cancer cells were treated
with, or without, 10 ng/ml of hVEGF165 in the presence or absence of Z-VAD-FMK (50 μM) and their invasion at 36 h post culture was determined by the transwell invasion
assay. Data are representative images and expressed as the mean ± SD of each group of cells from three separate experiments. (A) The effect of VEGF silencing on the in-
vasion of MDA-MB-231 cells; (B) The effect of NRP-1 silencing and exogenous hVEGF165 on the invasion of MDA-MB-231 cells; (C) The effect of NRP-1 over-expression and
exogenous hVEGF165 on the invasion of MCF-7 cells. *p < 0.05, **p < 0.01, ***p < 0.001 vs. the controls.
6 M. Luo et al./Cancer Letters 373 (2016) 1–11
action of VEGF/NRP-1 axis in regulating the migration and inva-
sion of breast cancer cells, the relative levels of E-cadherin, Occludin,
N-cadherin, Vimentin and Snail in VEGF or NRP-1 silencing breast
cancer cells were characterized by Western blot assays. In compar-
ison with that in the control MDA-MB-231/shNC cells, signiﬁcantly
increased levels of E-cadherin and Occludin, but decreased levels
of N-cadherin, Vimentin and Snail expressionwere detected inMDA-
MB-231/shVEGF cells (Fig. 5A). A similar pattern of E-cadherin,
Occludin, N-cadherin, Vimentin and Snail expression was de-
tected in MDA-MB-231/siNRP-1 cells, related to that in MDA-MB-
231/siNC cells (Fig. 5B). In contrast, the relative levels of E-cadherin
and Occludin signiﬁcantly decreased and the levels of N-cadherin,
Vimentin and Snail expression increased in MCF-7/NRP-1 cells, as
compared with that in the control MCF-7/NC cells (Fig. 5C). Inter-
estingly, treatment with hVEGF165 did not signiﬁcantly change the
relative levels of E-cadherin, Occludin, N-cadherin, Vimentin and
Snail expression in MDA-MB-231/siNRP-1 cells, but slightly changed
their expression in both MDA-MB-231/siNC andMCF-7/NRP-1 cells.
Together, these data suggest that the promotion of migration and
invasion of breast cancer cells by the VEGF/NRP-1 axis may be as-
sociated with the enhancement of EMT process.
The VEGF/NRP-1 axis regulates the NF-κB and β-catenin signaling in
breast cancer cells
Previous studies have shown that the NF-κB and β-catenin path-
ways are associated with regulating the migration and invasion of
breast cancer cells and are regulated by GSK-3β expression [17,18].
To understand the molecular mechanisms underlying the regula-
tion of VEGF/NRP-1 axis, the relative levels of NF-κBp65, β-catenin,
GSK-3β expression and NF-κBp65 and β-catenin phosphorylation
were determined by Western blot assays. As shown in Fig. 6A,
reduced levels of NF-κBp65 and β-catenin phosphorylation and in-
creased levels of GSK-3β expression were detected in MDA-MB-
231/shVEGF cells, related to that in the MDA-MB-231/shNC cells.
A similar pattern of the NF-κBp65 phosphorylation and GSK-3β
expression was detected in the MDA-MB-231/siNRP-1 and
MDA-MB-231/siNC cells (Fig. 6B). Induction of NRP-1 over-expression
signiﬁcantly enhanced the NF-κBp65 and β-catenin phosphoryla-
tion and reduced the levels of GSK-3β expression in MCF-7 cells
(Fig. 6C). Interestingly, treatment with hVEGF165 slightly increased
the levels of NF-κBp65 and β-catenin phosphorylation, but reduced
the levels of GSK-3β expression inMCF-7/NRP-1 cells (Fig. 6C). These
data suggest that the regulation of the VEGF/NRP-1 axis on the NF-
κB and β-catenin signaling may be associated with modulation of
GSK-3β expression in breast cancer cells. But the precise mecha-
nisms underlying the action of the VEGF/NRP-1 axis in regulating
the NF-κB and β-catenin signaling need to be further elucidated.
Knockdown of VEGF attenuates the growth and metastasis of breast
cancer in mice
Finally, the impact of VEGF silencing on the growth and metas-
tasis of implanted breast cancer was determined. The volumes in
the VEGF-silencing breast tumors were signiﬁcantly less than the
control tumors (Fig. 7A, p < 0.01). Tomographic optical imaging in-
dicated that the intensity of imaging signals in the control tumors
was obviously stronger than that in the VEGF-silencing tumors
(Fig. 7B). While many liver metastatic nodules were detected in four
out of six mice with the control MDA-MB-231/shNC tumors, only
two out of six mice with VEGF-silencing tumors developed a few
liver metastatic nodules (Fig. 7B). Quantitatively, analysis revealed
that the mean numbers of liver metastatic nodules in the control
mice were signiﬁcantly greater than that in the mice with VEGF-
silencing tumors (p < 0.05, Fig. 7D). Histological analysis clearly
visualized the metastatic tumor in the livers of mice (Fig. 7C). Im-
munohistochemistry analysis revealed that intensity of anti-PCNA
and anti-Vimentin staining in the control tumors was signiﬁ-
cantly stronger than that in the VEGF-silencing tumors (p < 0.05,
Fig. 7E). Because VEGF/NRP-1 axis affects the vascular formation, the
vascular density in the VEGF-silencing and control tumors was char-
acterized using anti-CD31 staining. The vascular density in the VEGF-
silencing tumors was much less than that in the control tumors
(p < 0.05, Supplementary Fig. S4). However, there was no obvious
Fig. 5. The VEGF/NRP-1 axis enhances the EMT process in breast cancer cells in vitro. The relative levels of the EMT regulator expression in different groups of cells cul-
tured in the presence or absence of 10 ng/ml of hVEGF165 were determined by Western blot assay. Data are representative images of individual proteins in different groups
of cells from three separate experiments. (A and B) The effect of VEGF or NRP-1 silencing on the EMT regulator expression in MDA-MB-231 cells. (C) The effect of NRP-1
over-expression on the EMT regulator expression in MCF-7 cells.
7M. Luo et al./Cancer Letters 373 (2016) 1–11
difference in the necrotic areas between the VEGF-silencing and
control tumors. Therefore, knockdown of VEGF inhibited the growth
and liver metastasis of implanted breast cancer in mice.
Discussion
Tumor invasion and metastasis are the leading causes of tumor-
relatedmortality in breast cancer patients. Previous ﬁndings indicate
that VEGF, through its VEGFR2, promotes angiogenesis, leading to
tumor metastasis [19,20]. Recent studies have found that the VEGF/
VEGFR1/2/NRP-1 axis regulates the survival, malignant progression
and invasion of several types of cancer cells, independent of VEGF-
induced angiogenesis [6,10]. In this study, we ﬁrst characterized VEGF
and NRP-1 expression in 48 primary breast cancer tissues and found
that the levels of VEGF and NRP-1 expression in breast cancer were
associated with lymph node metastasis in this population. Further-
more, higher levels of VEGF and NRP-1 expression were detected
in aggressively metastatic MDA-MB-231 and MDA-MB-435S cells,
but only moderate levels of VEGF and very little NRP-1 displayed
in less aggressive MCF-7 cells. These ﬁndings support the previ-
ous observation that NRP-1 expression is an independent predictor
of poor outcome in NSCLC patients [21]. Hence, VEGF and NRP-1
expression may serve as a biomarker for classiﬁcation of breast
cancers.
To understand the potential role of VEGF/NRP-1 axis, we gen-
erated VEGF or NRP-1 silencing MDA-MB-231 and NRP-1 over-
expressingMCF-7 cells. We found that knockdown of VEGF or NRP-1
inhibited the proliferation of MDA-MB-231 cells, but enhanced the
apoptosis of MDA-MB-231 cells. Although knockdown of VEGF sig-
niﬁcantly upregulated the NRP-1 expression, exogenous hVEGF165
failed to rescue the proliferation of NRP-1 silencing MDA-MB-231
cells and did not prevent the further apoptosis of NRP-1 silencing
MDA-MB-231 cells. Furthermore, knockdown of VEGF signiﬁ-
cantly inhibited the growth of implanted breast cancer in vivo. In
contrast, induction of NRP-1 over-expression enhanced the prolif-
eration of MCF-7 cells. These data were consistent with previous
ﬁndings that NRP-1 is crucial for VEGF-mediated cancer cell
proliferation and the VEGF/NRP-1 axis promotes the malignant pro-
gression [9,11]. It is reported that VEGF can bind to VEGFR2 and NRP-
1, and activate the Ras, MAPK and PI3K/AKT signaling [11,21], which
should promote the proliferation of cancer cells and prevent spon-
taneous apoptosis of cancer cells. Knockdown of VEGF or NRP-1
expression would withdraw the stimulator, leading to inhibition on
the proliferation of breast cancer cells and enhancing the apopto-
sis of cancer cells. The failure of exogenous hVEGF165 to stimulate
the proliferation of NRP-1-silencing breast cancer cells further sup-
ported the importance of NRP-1 in VEGF165-mediated signaling and
function [15,22]. These two lines of evidence support the notion that
NRP-1 may be a therapeutic target for intervention of breast cancer
[23].
Cancer metastasis is the major factor for poor outcome of pa-
tients and a previous study has shown that the VEGF/NRP-1 axis
regulates the invasion of RCC cells by modulating the EMT process
[11]. In this study, we found that knockdown of VEGF or NRP-1 ob-
viously changed MDA-MB-231 cells to an epithelial-like shape with
a smaller body size, while NRP-1 over-expressing MCF-7 cells dis-
played a mesenchymal-like shape with increased body size.
Furthermore, knockdown of VEGF or NRP-1 signiﬁcantly inhibited
the migration and invasion of MDA-MB-231 cells after treatment
with pan-caspase inhibitor Z-VAD-FMK, while induction of NRP-1
enhanced themigration and invasion of MCF-7 cells. Consistent with
these data, knockdown of VEGF or NRP-1 signiﬁcantly up-regulated
the levels of E-cadherin and Occludin, but down-regulated the levels
of N-cadherin, Vimentin and Snail expression in MDA-MB-231 cells.
These data clearly indicated that knockdown of VEGF or NRP-1 pro-
moted the MET process in MDA-MB-231 cells. Although VEGF
silencing signiﬁcantly up-regulated the levels of NRP-1 expres-
sion, exogenous hVEGF165 neither prevented the MET process nor
rescued the inhibition on the migration and invasion of NRP-1 si-
lencing MDA-MB-231 cells. In contrast, induction of NRP-1 over-
expression promoted the migration and invasion of MCF-7 cells,
accompanied by enhanced expression of N-cadherin, Vimentin and
Snail in MCF-7 cells, which were further enhanced by exogenous
hVEGF165. More importantly, knockdown of VEGF inhibited the liver
Fig. 6. Modulation of VEGF or NRP-1 expression changes the levels of NF-κB and β-catenin phosphorylation in breast cancer cells. The relative levels of NF-κBp65, β-catenin
and GSK-3β as well as NF-κBp65 and β-catenin phosphorylation in different groups of cells cultured in the presence or absence of 10 ng/ml of hVEGF165 were determined
by Western blot assays. Data are representative images of individual proteins in different groups of cells from three separate experiments. (A and B) The effect of VEGF or
NRP-1 silencing on the p-NF-κBp65, p-β-catenin and GSK-3β in MDA-MB-231 cells. (C) The effect of NRP-1 over-expression on the p-NF-κBp65, p-β-catenin and GSK-3β in
MCF-7 cells.
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Fig. 7. VEGF-silencing inhibits the growth and metastasis of implanted breast tumors in mice. Female nude mice were randomized and inoculated with MDA-MB-231/shNC or MDA-MB-231/shVEGF cells and the growth of
implanted breast tumors was monitored up to 28 days post inoculation. At the end, the mice were subjected to imaging analysis and the formed tumors and livers of individual mice were dissected. The formed tumors and
liver metastatic tumors were photoimaged. The numbers of liver metastatic tumors were counted in a blinded manner. Subsequently, the tumor tissue sections were stained by H&E and the PCNA and Vimentin expression in
the tumor sections were characterized by immunohistochemistry. Data are representative images and expressed as the mean values of individual mice. (A) The growth of inoculated breast tumors; (B) Tomographic optical
imaging analysis of the inoculated and liver metastatic tumors. (i) and (ii) The tumors formed from indicated cells; (iii) to (vi) The liver tissues from indicated mice were observed in macrography and tomographic optical
imaging analysis, GFP was used as reporter to show the metastasis; arrows indicate the metastatic nodules. (C) Representative H&E stained sections of micrometastases in the liver from the MDA-MB-231/shNC group; T, tumor;
L, liver. (D) Quantitative analysis of the numbers of liver metastatic tumors in different groups,*p < 0.05. (E) Immunohistochemistry analysis of tumor cells using anti-PCNA and anti-Vimentin staining.
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metastasis of MDA-MB-231 tumors by reducing the PCNA and
Vimentin expression in tumor tissues in vivo. Apparently, the VEGF/
NRP-1 axis may promote the EMT process to maintain the
mesenchymal phenotype of breast cancer cells [21,24–26], which
is associated with the initiation of cancer metastasis [27–30]. Indeed,
previous studies have shown that the VEGF/NRP-1 axis promotes
the EMT process in pancreatic, lung and glioblastoma cancer cells
[29–32]. Hence, our ﬁndings extended previous observations that
the VEGF/NRP-1 axis may promote the metastasis by enhancing the
EMT process in breast cancer. These ﬁndings further support the
notion that the VEGF/NRP-1 axis may be a valuable target for in-
tervention of breast cancer.
Previous studies have shown that the VEGF/NRP-1 axis can ac-
tivate the k-Raf and downstreamMAPK to promote the proliferation
and invasion of glioblastoma and pancreatic cancer cells [33,34]. Ab-
errant activation of the NF-κB signaling is associated with migration
and invasion of breast cancer cells and the NF-κB signaling is down-
regulated by GSK-3β [35]. We found that knockdown of VEGF or
NRP-1 signiﬁcantly reduced the levels of NF-κBp65 phosphoryla-
tion, but up-regulated the levels of GSK-3β expression in MDA-MB-
231 cells. In contrast, induction of NRP-1 over-expression signiﬁcantly
enhanced the levels of NF-κBp65 phosphorylation, but reduced the
GSK-3β expression inMCF-7 cells. Furthermore, exogenous hVEGF165
failed to change the inhibition on NF-κB signaling and GSK-3β ex-
pression in NRP-1 silencing MDA-MB-231 cells, but it did slightly
enhance the levels of NF-κBp65 phosphorylation and decreased the
levels of GSK-3β expression in NRP-1 over-expressing MCF-7 cells.
Previous studies have shown that increased GSK-3β expression in-
hibits the proliferation of breast cancer cells by down-regulating
cyclin D1 expression and glucose response of breast cancer cells
through down-regulating the NF-κB activation [36,37]. It is possi-
ble that the VEGF/NRP-1 axis may, through the similar pathways,
down-regulate the activation of NF-κB signaling and the EMT process
in breast cancer cells. Of note, we also found that enhanced NRP-1
expression increased β-catenin phosphorylation in MCF-7 cells,
which was inconsistent with the canonical GSK-3β/β-catenin reg-
ulation pathway. Our ﬁndings also suggest that other mechanisms
may explain the observations. First, β-catenin functions in a dual
manner in epithelial cells, depending on the intracellular localiza-
tion [38].It is reported that E-cadherin-based cell–cell adhesion limits
the Wnt signal by promoting the activity of a junction localized
β-catenin phosphodestruction complex, which maybe relevant to
tissue morphogenesis [39]. Indeed, disruption of E-cadherin can
promote β-catenin-regulated transcription. Elevated E-cadherin ex-
pression can sequester β-catenin, thereby depleting the pool that
binds to LEF/TCF. Alternatively, it is possible that multiple forms of
β-catenin may exist in cells. Some β-catenin may be dependent on
the Wnt signaling and others may bind to E-cadherin. They are
interconvertible in the cells, or one form is an intermediate of
another, and can be depleted during its generation. Actually, we found
that knockdown of VEGF or NRP-1 increased the relative levels of
E-cadherin, which might attract more β-catenin in the cell surface,
leading to less β-catenin phosphorylation, possible for less β-catenin
nuclear translocation and signaling in MDA-MB-231 cells. We are
interested in further investigating the precise mechanisms under-
lying the action of VEGF/NRP-1 in regulating the EMT andmetastasis
of breast cancer.
In summary, our data indicated that higher levels of VEGF and
NRP-1 expression were associated with aggressiveness of breast
cancer. Knockdown of VEGF or NRP-1 inhibited the proliferation,
migration and invasion and attenuated the EMT process in breast
cancer cells, which may be associated with inhibiting aberrant ac-
tivation of the NF-κBp65 signaling and up-regulating the GSK-3β
expression. Induction of NRP-1 over-expression reversed the effects
in MCF-7 cells. In addition, our data also suggest that the β-catenin
signaling may be involved in this process although the precise
mechanisms need to be further elucidated. Moreover, knockdown
of VEGF inhibited the growth and livermetastasis of implanted breast
cancer in mice. Nevertheless, our study may provide a proof of prin-
ciple for the VEGF/NRP-1 axis promoting the proliferation and
metastasis of breast cancer. We recognized that our studies had limi-
tations. First, we cannot exclude the effect of VEGF-silencing on
angiogenesis, whichmay deﬁnitely affect the tumor growth andme-
tastasis of breast cancer in vivo. Second, VEGF has several different
receptors, which may play different roles in combination or inde-
pendently in the regulation of VEGF/NRP-1 axis. Third, NRP-1 is a
multifunctional receptor and can be stimulated by several ligands,
such as Semaphorin 3A, HGF, bFGF and others. The precise effect
of targeting NRP-1 on the growth of breast cancer remains to be
investigated.
In conclusion, our data suggest that the VEGF/NRP-1 axis may
promote the growth and metastasis of breast cancer in an autocrine
manner. Hence, the VEGF/NRP-1 axis may be a valuable target for
design of therapies for intervention of breast cancer. Our novel ﬁnd-
ings may provide new insights into regulating the growth and
metastasis of breast cancer.
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